Favipiravir treatment prolongs the survival in a lethal mouse model intracerebrally inoculated with Jamestown Canyon virus.
Amides
/ administration & dosage
Animals
Antiviral Agents
/ administration & dosage
Chlorocebus aethiops
Disease Models, Animal
Drug Evaluation, Preclinical
Encephalitis Virus, California
/ drug effects
Encephalitis, California
/ drug therapy
Female
Humans
Mice
Mice, Inbred C57BL
Pyrazines
/ administration & dosage
Vero Cells
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
18
11
2020
accepted:
08
06
2021
revised:
15
07
2021
pubmed:
3
7
2021
medline:
12
11
2021
entrez:
2
7
2021
Statut:
epublish
Résumé
Jamestown Canyon virus (JCV) is a mosquito-borne orthobunyavirus that causes acute febrile illness, meningitis, and meningoencephalitis, primarily in North American adults. Currently, there are no available vaccines or specific treatments against JCV infections. The antiviral efficacy of favipiravir (FPV) against JCV infection was evaluated in vitro and in vivo in comparison with that of ribavirin (RBV) and 2'-fluoro-2'-deoxycytidine (2'-FdC). The in vitro inhibitory effect of these drugs on JCV replication was evaluated in Vero and Neuro-2a (N2A) cells. The efficacy of FPV in the treatment of JCV infection in vivo was evaluated in C57BL/6J mice inoculated intracerebrally with JCV, as per the survival, viral titers in the brain, and viral RNA load in the blood. The 90% inhibitory concentrations (IC90) of FPV, RBV, and 2'-FdC were 41.0, 61.8, and 13.6 μM in Vero cells and 20.7, 25.8, and 8.8 μM in N2A cells, respectively. All mice infected with 1.0×104 TCID50 died or were sacrificed within 10 days post-infection (dpi) without treatment. However, mice treated with FPV for 5 days [initiated either 2 days prior to infection (-2 dpi-2 dpi) or on the day of infection (0 dpi-4 dpi)] survived significantly longer than control mice, administered with PBS (p = 0.025 and 0.011, respectively). Moreover, at 1 and 3 dpi, the virus titers in the brain were significantly lower in FPV-treated mice (0 dpi-4 dpi) versus PBS-treated mice (p = 0.002 for both 1 and 3 dpi). Although the intracerebral inoculation route is thought to be a challenging way to evaluate drug efficacy, FPV inhibits the in vitro replication of JCV and prolongs the survival of mice intracerebrally inoculated with JCV. These results will enable the development of a specific antiviral treatment against JCV infections and establishment of an effective animal model.
Sections du résumé
BACKGROUND
Jamestown Canyon virus (JCV) is a mosquito-borne orthobunyavirus that causes acute febrile illness, meningitis, and meningoencephalitis, primarily in North American adults. Currently, there are no available vaccines or specific treatments against JCV infections.
METHODOLOGY/PRINCIPAL FINDINGS
The antiviral efficacy of favipiravir (FPV) against JCV infection was evaluated in vitro and in vivo in comparison with that of ribavirin (RBV) and 2'-fluoro-2'-deoxycytidine (2'-FdC). The in vitro inhibitory effect of these drugs on JCV replication was evaluated in Vero and Neuro-2a (N2A) cells. The efficacy of FPV in the treatment of JCV infection in vivo was evaluated in C57BL/6J mice inoculated intracerebrally with JCV, as per the survival, viral titers in the brain, and viral RNA load in the blood. The 90% inhibitory concentrations (IC90) of FPV, RBV, and 2'-FdC were 41.0, 61.8, and 13.6 μM in Vero cells and 20.7, 25.8, and 8.8 μM in N2A cells, respectively. All mice infected with 1.0×104 TCID50 died or were sacrificed within 10 days post-infection (dpi) without treatment. However, mice treated with FPV for 5 days [initiated either 2 days prior to infection (-2 dpi-2 dpi) or on the day of infection (0 dpi-4 dpi)] survived significantly longer than control mice, administered with PBS (p = 0.025 and 0.011, respectively). Moreover, at 1 and 3 dpi, the virus titers in the brain were significantly lower in FPV-treated mice (0 dpi-4 dpi) versus PBS-treated mice (p = 0.002 for both 1 and 3 dpi).
CONCLUSIONS/SIGNIFICANCE
Although the intracerebral inoculation route is thought to be a challenging way to evaluate drug efficacy, FPV inhibits the in vitro replication of JCV and prolongs the survival of mice intracerebrally inoculated with JCV. These results will enable the development of a specific antiviral treatment against JCV infections and establishment of an effective animal model.
Identifiants
pubmed: 34214091
doi: 10.1371/journal.pntd.0009553
pii: PNTD-D-20-02022
pmc: PMC8281987
doi:
Substances chimiques
Amides
0
Antiviral Agents
0
Pyrazines
0
favipiravir
EW5GL2X7E0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0009553Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: N.N., T.K., and Y.F. are employees of FUJIFILM Toyama Chemical Co., Ltd, and Y.F. is the inventor of FPV.
Références
J Neurovirol. 2016 Jun;22(3):257-60
pubmed: 26903031
Antiviral Res. 2009 Jun;82(3):169-71
pubmed: 19428608
Ann Neurol. 2001 Jun;49(6):810-3
pubmed: 11409437
Engineering (Beijing). 2020 Oct;6(10):1192-1198
pubmed: 32346491
J Wildl Dis. 1987 Jan;23(1):23-33
pubmed: 3820426
Antimicrob Agents Chemother. 2010 Jun;54(6):2517-24
pubmed: 20350949
Antiviral Res. 2017 Nov;147:91-99
pubmed: 29024765
MMWR Morb Mortal Wkly Rep. 2018 Oct 19;67(41):1137-1142
pubmed: 30335737
mSphere. 2016 Jan 06;1(1):
pubmed: 27303697
Pediatr Infect Dis J. 2011 Oct;30(10):860-5
pubmed: 21544005
J Infect Dis. 2019 Jun 19;220(2):195-202
pubmed: 30788508
Am J Trop Med Hyg. 2006 Nov;75(5):1011-6
pubmed: 17124004
J Antimicrob Chemother. 1984 Aug;14 Suppl A:27-41
pubmed: 6208183
Antiviral Res. 2008 Dec;80(3):377-9
pubmed: 18762216
Antiviral Res. 1986 Aug;6(5):285-97
pubmed: 2429616
PLoS Negl Trop Dis. 2014 May 01;8(5):e2804
pubmed: 24786461
J Med Virol. 1988 Sep;26(1):79-84
pubmed: 2846772
Am J Trop Med Hyg. 2019 Feb;100(2):445-451
pubmed: 30526745
Emerg Infect Dis. 2019 Apr;25(4):728-738
pubmed: 30882310
BMC Infect Dis. 2020 Oct 23;20(1):790
pubmed: 33096994
Jpn J Infect Dis. 2014;67(6):423-7
pubmed: 25410555
J Virol. 2012 Jan;86(1):420-6
pubmed: 22013033
Vector Borne Zoonotic Dis. 2008 Apr;8(2):175-88
pubmed: 18386967
Arch Virol. 2019 Jul;164(7):1949-1965
pubmed: 31065850
Antimicrob Agents Chemother. 1989 Nov;33(11):2009-11
pubmed: 2610511
Virol J. 2011 Mar 24;8:136
pubmed: 21435230
MMWR Morb Mortal Wkly Rep. 2019 Aug 09;68(31):673-678
pubmed: 31393865
Antimicrob Agents Chemother. 2007 Sep;51(9):3168-76
pubmed: 17606691
Epilepsia Open. 2018 Apr 17;3(2):286-289
pubmed: 29881809
J Infect Dis. 2016 Apr 15;213(8):1253-61
pubmed: 26655300
Antimicrob Agents Chemother. 1981 Jun;19(6):1042-9
pubmed: 7271273
Can Commun Dis Rep. 2015 Jun 04;41(6):117-123
pubmed: 29769943
Antiviral Res. 2013 Nov;100(2):446-54
pubmed: 24084488
PLoS Med. 2016 Mar 01;13(3):e1001967
pubmed: 26930627
Prog Clin Biol Res. 1983;123:1-16
pubmed: 6346334
Antiviral Res. 2018 Dec;160:48-54
pubmed: 30339848
Am J Trop Med Hyg. 2015 Feb;92(2):377-93
pubmed: 25487728
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463
pubmed: 28769016
Am J Trop Med Hyg. 2015 Aug;93(2):384-9
pubmed: 26033022
Clin Infect Dis. 1999 Jun;28(6):1294-7
pubmed: 10451169
Antimicrob Agents Chemother. 2002 Apr;46(4):977-81
pubmed: 11897578
Int J Infect Dis. 2021 Jan;102:501-508
pubmed: 33130203
PLoS One. 2019 Oct 7;14(10):e0223684
pubmed: 31589656
PLoS Negl Trop Dis. 2018 Apr 16;12(4):e0006398
pubmed: 29659579